FINWIRES · TerminalLIVE
FINWIRES

生物燃料最新動態:大豆油和棕櫚油價格上漲;乙醇價格上漲

-- 儘管出口趨勢背離,芝加哥大豆期貨和馬來西亞棕櫚油期貨週二均走強。 芝加哥期貨交易所5月大豆期貨合約上漲0.49%,至每蒲式耳11.71美元;5月豆油期貨合約早盤小幅上漲1.26%,至每磅70.51美分。 根據週一公佈的農業數據,截至4月16日當週,美國大豆出口檢驗量增至748,678公噸,高於前一周的738,786公噸,也高於去年同期的560,009公噸。 中國成為最大的出口目的地,當週出口量為446,146公噸,其次是埃及(117,568公噸)和日本(76,804公噸)。 本銷售年度的出貨量為3,220萬噸,仍遠低於上年的4,270萬噸。 數據顯示,截至4月19日,美國大豆種植進度已達12%,高於上一季的7%及五年平均5%。 根據《中國日報》引述的農業展望報告顯示,由於農業技術的進步和土地利用效率的提高,中國今年的國內糧食產量可能會增加,這可能導致大豆進口量比去年同期下降6.1%。 根據《中東和非洲製粉雜誌》報道,中國進口成長放緩將主要影響巴西和美國的出口市場,並可能重塑全球供應鏈。 根據Barchart引述AgRural的估計,截至4月16日,巴西大豆作物已完成92%的收割。 週二,儘管出口疲軟,馬來西亞棕櫚油期貨價格仍小幅上漲,競爭對手大豆油價格也隨之走高。 馬來西亞衍生性商品交易所(Bursa Malaysia Derivatives)5月交割的原棕櫚油合約上漲0.81%,至每噸4491馬來西亞林吉特(1,135.24美元)。 6月交割的合約上漲1.07%,至每噸4535林吉特。 根據Phillip Capital和Trading Economics報告,貨運調查員估計,4月前20天馬來西亞的棕櫚油出貨量較上月下降了25.6%至25.8%。 價格報告機構Fastmarkets的分析顯示,由於近期產品成本和運費飆升,馬來西亞對大多數區域目的地的出口在4月上半月出現下滑,其中對中東的出口降幅最大。 據該機構引用Intertek Testing Services的數據,4月1日至15日期間,出口量較上季下降324,724噸至580,018噸,主要原因是中東地區的出口量減少了114,650噸。 據報道,對印度的出口量從150,600噸減少至102,300噸,而對中國的出口量則從67,550噸減少至54,760噸。 印度的採購量可能會在季節性需求到來之前反彈,但由於經濟狀況不佳,中國的進口量可能仍將面臨壓力。 中國價格報告機構MySteel表示,在中國,“國內進口利潤率仍然嚴重倒掛,導致船舶採購量很少,甚至有兩艘船取消了訂單,但港口庫存仍然很高。” MySteel表示,棕櫚油市場基本面整體走軟,出口下降而產量上升,形成「供過於求」的局面。 Fastmarkets指出,馬來西亞棕櫚油產量在第一季度跌至季節性低點後預計將有所回升,這可能會限制國內庫存的下降幅度。 儘管如此,如果原油價格持續走強,提振生質燃料需求,棕櫚油價格可能仍將得到支撐。 印尼計劃從7月1日起將生質柴油比例從目前的40%提高到50%,而馬來西亞正努力將生質柴油比例從目前的10%提高到12%和15%,但具體時間表尚未確定。 在美國,紐約商品交易所(NYMEX)5月交割的乙醇期貨週一結束了連續四個交易日的下跌,反彈0.13%,至每加侖約1.90美元。 市場目前正等待將於週三公佈的每週產量、庫存和出口數據。

Related Articles

Asia

Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies

Clinuvel Pharmaceuticals (ASX:CUV) is unlikely to seek regulatory approval for Scenesse in vitiligo until the Phase 3 CUV105 and CUV107 clinical trials are completed, according to a Friday Jefferies note.The company said on Friday that the European Medicines Agency (EMA) has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a "totality of evidence" regulatory approach.Jefferies said that the EMA's decision is a positive for the company because of the high unmet medical need for Vitiligo treatment.The investment firm has pushed back its revenue expectations from Scenesse in vitiligo, which is now expected to begin in the second half of fiscal 2029 rather than fiscal 2028.Jefferies kept a buy rating on Clinuvel and cut its price target to AU$39.20 from AU$40.50.

$ASX:CUV
Asia

ASX Preview: Australian Shares Set to Open Flat on Stalled US-Iran Talks; Origin Energy Reports Lower March Quarter Production

Australian shares are set to open flat on Monday, as oil prices climbed almost 2% following stalled US-Iran peace negotiations and restricted flows through the Strait of Hormuz, tightening global supply and pushing Brent crude above $107 a barrel.On April 25, the S&P 500 and the Nasdaq Composite rose 0.8% and 1.6%, respectively, while the Dow Jones Industrial Average fell 0.2%.In the macroeconomy, investors are eyeing the release of Australia's consumer price index report on Wednesday.In corporate news, Origin Energy (ASX:ORG) reported March quarter production of 164.5 petajoules, down from 167.1 petajoules a year earlier, according to a Monday filing with the Australian bourse.IperionX's (ASX:IPX) titanium powder production operations in Virginia, US, transitioned to an around-the-clock production schedule during the March quarter, advancing from commissioning to continuous operations, according to a Monday filing with the Australian bourse.Australia's benchmark index fell 0.1% or 6.9 points to close at 8,786.50 on April 24.

$^AXJO$ASX:IPX$ASX:ORG
Asia

Cobre Appoints Chief Financial Officer

Cobre (ASX:CBE) has appointed Kaveen Bachoo as chief financial officer, effective April 28, according to a Monday filing with the Australian bourse.Bachoo has over 20 years of finance leadership experience in the mining sector, including executive positions at Glencore.

$ASX:CBE